Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Retained Earnings (2016 - 2026)

Summit Therapeutics filings provide 13 years of Retained Earnings readings, the most recent being -$2.5 billion for Q1 2026.

  • Quarterly Retained Earnings fell 94.41% to -$2.5 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.5 billion through Mar 2026, down 94.41% year-over-year, with the annual reading at -$2.5 million for FY2025, 99.79% up from the prior year.
  • Retained Earnings hit -$2.5 billion in Q1 2026 for Summit Therapeutics, down from -$2.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$2.3 million in Q3 2024 and bottomed at -$2.5 billion in Q1 2026.
  • Average Retained Earnings over 5 years is -$704.4 million, with a median of -$378.3 million recorded in 2022.
  • Peak annual rise in Retained Earnings hit 99.79% in 2025, while the deepest fall reached 89804.12% in 2025.
  • Summit Therapeutics' Retained Earnings stood at -$378.3 million in 2022, then skyrocketed by 99.35% to -$2.4 million in 2023, then crashed by 49514.91% to -$1.2 billion in 2024, then soared by 99.79% to -$2.5 million in 2025, then plummeted by 97678.86% to -$2.5 billion in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Retained Earnings are -$2.5 billion (Q1 2026), -$2.5 million (Q4 2025), and -$2.1 billion (Q3 2025).